Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Tuzun E., LI J., SAINI S. S., YANG H., CHRISTADOSS P.

JOURNAL OF NEUROIMMUNOLOGY, cilt.182, ss.167-176, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 182
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.jneuroim.2006.10.014
  • Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.167-176
  • Anahtar Kelimeler: C1q, classical complement pathway, myasthenia gravis, autoimmunity, EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS, CIRCULATING IMMUNE-COMPLEXES, T-CELL PROLIFERATION, C1 INHIBITOR, COMPLEMENT INHIBITOR, GENETIC-EVIDENCE, MOTOR ENDPLATE, MICE, C3, PATHOGENESIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 mu g or 100 mu g of anti-C1q Ab or isotype Ab. Treatment with 10 mu g anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 mu g anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy. (c) 2006 Elsevier B.V. All rights reserved.